We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Circulating Immune Cells Act As Idiopathic Pulmonary Fibrosis Biomarkers

By LabMedica International staff writers
Posted on 14 Sep 2016
Image: The BD LSRII flow cytometer (Photo courtesy of Becton Dickinson).
Image: The BD LSRII flow cytometer (Photo courtesy of Becton Dickinson).
Patients with fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), show progressive worsening of lung function with increased shortness of breath and dry cough.

To-date, this process is irreversible, which is why scientists are searching for novel biomarkers or indicators, which enable earlier diagnosis of this disease, with the aim to better interfere with disease progression.

Scientists at the Helmholtz Zentrum München (Munich, Germany) prospectively included 170 patients in the analysis, divided into 69 IPF, 56 non-IPF interstitial lung disease (ILD), 17 with hypersensitivity pneumonitis, 27 with nonspecific interstitial pneumonia, 12 with connective tissue disease- (ILD), and 23 chronic obstructive pulmonary disease (COPD) patients, as well as 22 healthy controls.

For immunophenotyping, the team collected fresh venous blood in EDTA-coated vacutainer tubes. Briefly, whole blood or peripheral blood mononuclear cell (PBMC) buffy coats were used for flow cytometry detection of myeloid-derived suppressor cells (MDSC) and lymphocyte subtypes. Erythrocytes were lysed with a Coulter Q-Prep working station (Beckman Coulter, Brea, CA, USA). Data acquisition was performed in a BD LSRII flow cytometer or a BD fluorescence-activated cell sorter (FACS) ARIA II (Becton Dickinson, Heidelberg, Germany) if cells were sorted. The T-cell suppression assay and MDSC co-cultures were also performed.

Peripheral blood mononuclear cell (PBMC) Messenger ribonucleic acid (mRNA) levels were analyzed by real time polymerase chain reaction (qRT-PCR). The investigators detected increased MDSC in IPF and non-IPF ILD compared with controls (30.99 ± 15.61% versus 18.96 ± 8.17%). Circulating MDSC inversely correlated with maximum vital capacity in IPF, but not in COPD or non-IPF ILD. MDSC suppressed autologous T-cells. The mRNA levels of co-stimulatory T-cell signals were significantly downregulated in IPF PBMC. Importantly, CD33+CD11b+ cells, suggestive of MDSC, were detected in fibrotic niches of IPF lungs.

Oliver Eickelberg, MD, a professor and lead investigator said, “We were able to show that MDSC are primarily found in fibrotic niches of IPF lungs characterized by increased interstitial tissue and scarring, that is, in regions where the disease is very pronounced, and as a next step, we seek to investigate whether the presence of MDSC can serve as a biomarker to detect IPF and to determine how pronounced it is. Controlling accumulation or expansion of MDSC or blocking their suppressive functions may represent a promising treatment options for patients with IPF. ” The study was published on September 1, 2016, in the European Respiratory Journal.

Related Links:
Helmholtz Zentrum München
Beckman Coulter
Becton Dickinson
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
POC Immunoassay Analyzer
Procise DX

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more